Assessment of influence of the long-term treatment with inhaled glucocorticoid on growth and body weight in asthmatic children aged 6 to 24 month
Abstract
Background: Inhaled glucocorticoids are drugs of the first choice for the asthma treatment. Their growth suppressive potential is well known. It has been suggested that it may wane off during the first year of treatment. It has been also suspected that asthmatic children might become overweight/obese after asthma therapy. The aim of this prospective study was to assess the influence of long-term treatment with fluticasone propionate (FP) on body weight and growth in asthmatic children aged 6 to 24 month.
Methods: 26 pairs of children of the same age with birth weight > 3000 g took part in 12-month parallel group trial. Group A consisted of children with mild persistent asthma treated for the first time. Inhaled FP 100 µg twice daily was used. Group B consisted of healthy children. In each group there were 17 males and 9 females. Weight and height data during 6-month prior to enrolment in the trial were retrospectively collected from the notes. Length and weight of both children from a pair were measured on the same day from day 1 every 3 month up to a year on the same measuring instrument. SPSS software 10.0 was used for statistical analyses. t-tests were employed for between-group analyses.
Results: Mean weight was greater for 156 g in group A (t = 0.29, p = 0.77, DF: 24), and the mean length increase was greater for 0.72 cm in group B (t = –1.06, p = 0.30, DF: 24). The differences between group A and B were not statistically significant. A marked decrease in mean length difference from 0.26 in the first to 0.09 cm in the last quarter of the study was observed.
Conclusions: Long-term treatment with inhaled glucocorticoids (100 µg FP twice daily) is safe in spite to their suppressive effect on growth. The growth suppressive potential of inhaled glucocorticoids is decreasing during the treatment. There is a no significant influence on body weight.
Downloads
References
Kopriva S, Maček V, Župevc M, Kos M, Kopriva-Pirtovšek K. Epidemiologija astme pri otrocih v Sloveniji. Astma pri otroku. Ljubljana: Klinični center, Pediatrična klinika, Služba za pulmologijo; 2003. p. 7–17.
Maček V. Diagnoza in diferencialna diagnoza astme. Astma pri otroku. Ljubljana: Klinični center, Pediatrična klinika, Služba za pulmologijo; 2003. p. 39–45.
Sly M. Allergic disorders. In: Behrman RE, Kliegman RM, Jenson HB. Nelson textbook of pediatrics. 16th ed. Vol. 1. Philadelphia: W. B. Saunders; 2000. p, 664–80.
Kern I. Patologija astme. Astma. Golnik: Klinika za pljučne bolezni in alergijo; 2000.
Černelč M. Preventivna zdravila za zdravljenje astme pri otroku. Astma pri otroku. Ljubljana: Klinični center, Pediatrična klinika, Služba za pulmologijo; 2003. p. 95–101.
Camargo CA Jr, Weiss ST, Zhang S, Willett WC, Speizer FE. Prospective study of bodi mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999; 159: 2582–8.
Von Kries R, Hermann M, Grunert VP, von Mutius E. Is obesity a risk factor for childhood asthma? Allergy 2001; 56: 318–22.
Accetto M. Alergijska astma: patogeneza, klinična slika in diagnostika. Pediatrična alergologija. Ljubljana: Klinični center, Pediatrična klinika, Služba za alergologijo in revmatske bolezni; 2002. p. 93–101.
The Childhood Asthma Management Program Research Group. Long term effects of budesonide and nedocromil in children with asthma. N Engl J Med 2000; 347: 1054–63.
Černelč M. Razvoj obstruktivnega sindroma v astmo. Astma pri otroku. Ljubljana: Pediatrična klinika; 1999.
Knorr B, Franchi LM, Bizgaard F, Vermevlen JH, LeSovess P, Santanello N, et al. Montelukast, a leukotriene receptorantagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics (serial on line) 2001 (citirano 21. februarja 2002); 108(3): (10 screens). Dosegljivo na: AAP: http://www.pediatrics.org/cgi/content/full/108/3/e48.
Doull IJ, Freezer NJ, Holgate ST. Grouth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995; 151: 1715–9.
Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on grouth. J Allergy Clin Immunol 1994; 93: 967–76.
Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 1064–9.
Heuck C, Wolters OD, Kollerup G, Hansen M, Teisner B. Adverse effects of inhaled budesonide (800 µg) on grouth and collagen turnover in children with asthma: a double-blind comparison of once-daily versus twice-daily administration. J Pediatr 1998; 133: 608–12.
Shaheen SO, Sterne JA, Montgomery SM, Azima H. Birth weight, body mass index and astma in young adults. Thorax 1999; 55: 396–402.
Gennuso J, Epstein LH, Paluch RA, Cerny F. The relationship between asthma and obesity in urban minority children and adolescents. Arch Pediatr Adolesc Med 1998; 152: 1197–200.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
